Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31644586 | 1.00 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP2C19TOP2ACYP4F2 | |
| SCHEMBL30879175 | 0.93 | POLB (0.41) | CYP3A4CYP2D6CYP2C19TOP2ACYP4F2 | |
| SCHEMBL17006101 | 0.86 | TBXAS1 (0.37) | CYP2D6CYP2C19ALDH1A1SMN1; SMN2TBXAS1 | |
| SCHEMBL29925577 | 0.85 | TSHR (0.43) | ALDH1A1POLB | |
| SCHEMBL9689889 | 0.85 | TSHR (0.43) | ALDH1A1POLB | |
| SCHEMBL29198555 | 0.85 | TSHR (0.43) | ALDH1A1POLB | |
| SCHEMBL6749218 | 0.83 | CTSK (0.35) | ALDH1A1POLB | |
| SCHEMBL4527172 | 0.83 | CTSK (0.35) | ALDH1A1POLB | |
| SCHEMBL8892070 | 0.80 | FFAR1 (0.37) | CYP2D6CYP2C19ALDH1A1ALOX5TBXAS1 | |
| SCHEMBL8174758 | 0.80 | ALDH1A1 (0.36) | CYP3A4ALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273067-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273067-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2015126737-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | TYMP, EIF2AK2, MAVS | CYP3A4 619/4885CYP2D6 642/4885CYP2C19 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.